- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01686360
Communicating Objective Risk for Personalized Decision Making About Mammography
Studieoversikt
Detaljert beskrivelse
This study will compare alternative strategies for the presentation of individualized information about the risks and benefits of mammography screening. The purpose of this study is to understand how objective risk information influences outcomes including behavioral intentions, attitudes about mammography, and emotional responses.
After participants view objective risk information, a post-test survey will measure outcome variables including behavioral intentions, knowledge, and emotional responses.
After reading information based on their condition, study participants will be asked to complete a series of questions to measure their reactions based on their condition. Specifically, the investigators will be measuring the following dependent variables (primary outcomes): behavioral intentions to receive mammograms, attitudes about mammography, subjective norms about mammography and breast cancer screening, knowledge about mammography outcomes and screening recommendations, and emotional responses to the material including psychological reactance. These outcomes will be measured using self-reported questionnaire items.
In this project, the investigators will compare alternative communication strategies to determine which strategy or strategies result in the greatest level of understanding. The investigators also will examine if the various strategies differentially affect the primary outcomes listed above.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- University of Pennsylvania
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adult women between the ages of 35 and 49 will be invited to participate in this study.
Exclusion Criteria:
- Women who have been previously diagnosed with breast cancer or have tested positive for the breast cancer gene will not be included.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Faktoriell oppgave
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Ingen inngripen: Control group 1: pre/post-test
Group receives pre and post test questions only.
|
|
Eksperimentell: Control group 2: tool and pre/post-test
Group receives decision tool without personalized information.
(Behavioral: Decision Aid)
|
|
Eksperimentell: Gail score in a percentage format
Group receives Gail score in a percentage format.
(Behavioral: Decision Aid)
|
|
Eksperimentell: Gail score in a frequency format
Group receives Gail score in a frequency format.
(Behavioral: Decision Aid)
|
|
Eksperimentell: Frequency + Average 50 year old
Group receives Gail score in a frequency format as well as information about risk of breast cancer for the average 50 year old woman.
(Behavioral: Decision Aid)
|
|
Eksperimentell: Frequency + Mammography Data
Group receives Gail score in a frequency format as well as information about the risks of mammography.
(Behavioral: Decision Aid)
|
|
Eksperimentell: Frequency + Mortality Data
Group receives Gail score in a frequency format as well as information about mortality benefit of mammography.
(Behavioral:Decision Aid)
|
|
Eksperimentell: Frequency + Avg 50 year old + Mamm Data + Mortality Data
Group receives Gail score in a frequency format as well as information about breast cancer risk for the average 50 year old woman, information about the risks of mammography, risk of breast cancer for the average 50 year old woman, and information about the mortality benefit associated with mammography.
(Behavioral: Decision Aid)
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Behavioral intentions to get a mammogram
Tidsramme: immediately following intervention (time 0)
|
All participants will be asked to report their behavioral intentions to obtain mammograms in their 40s and at age 50.
|
immediately following intervention (time 0)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Attitude about mammography
Tidsramme: immediately following intervention (time 0)
|
Participants will be asked to report their attitudes about mammography (i.e., is a mammogram useful, harmful, etc.)
|
immediately following intervention (time 0)
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Injunctive and descriptive norms about mammography
Tidsramme: immediately following intervention (time 0)
|
Participants will be asked to report their perceived norms about mammography, what they think important others would expect them to do and what they think other women their age or older are doing.
|
immediately following intervention (time 0)
|
Decisional satisfaction
Tidsramme: immediately following intervention (time 0)
|
This variable assesses how satisfied participants feel about making a decision about mammography given the information they have been provided.
Items include, "The information in the decision aid made me feel the choice to get a mammogram is being taken away from me by the groups that make screening recommendations."
|
immediately following intervention (time 0)
|
Risk perception
Tidsramme: immediately before and after intervention (time 0)
|
This variable includes perceived severity and perceived susceptibility of breast cancer.
Items include, "What is the chance that an average 40-49 year old woman will develop breast cancer in the next 10 years?
Please choose a number between 0 (no chance of breast cancer) and 100 (definitely will get breast cancer)."
|
immediately before and after intervention (time 0)
|
Clarity of the information being presented
Tidsramme: immediately following intervention (time 0)
|
These items assess how easy it is for participants to understand the numerical information that is provided in the decision aid.
|
immediately following intervention (time 0)
|
Credibility of the information
Tidsramme: immediately following intervention (time 0)
|
These items measure the perceived trustworthiness, credibility, and accuracy of the information provided in the decision aid.
Items include, "How credible did you find the information presented in the decision aid?"
|
immediately following intervention (time 0)
|
Emotional reactions
Tidsramme: immediately following intervention (time 0)
|
The outcome includes measures of psychological reactance, anger, and fear that may be possible reactions to the decision aid.
Items include, "How much do each of the following words (i.e., angry, worried) describe how you felt while reading the decision aid?"
|
immediately following intervention (time 0)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Joseph N Cappella, PhD, University of Pennsylvania
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 816186
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Brystkreft
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbeidspartnereFullførtThe Clinical Application Guide of Conebeam Breast CTKina
-
Novartis PharmaceuticalsFullførtMetastatisk brystkreft (MBC) | Locally Advance Breast Cancer (LABC)Storbritannia, Spania
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
Emory UniversityNational Cancer Institute (NCI)TilbaketrukketPrognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i hjernen | Metastatisk brystkarsinom | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnatomisk stadium IV brystkreft AJCC v8 | Prognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i beinet | Metastatisk malign neoplasma i lymfeknutene | Metastatisk malign neoplasma i leveren | Metastatisk brystkarsinom | Metastatisk malign neoplasma i lungen | Metastatisk malign neoplasma... og andre forholdForente stater, Canada, Saudi-Arabia, Korea, Republikken
Kliniske studier på Beslutningshjelp
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) og andre samarbeidspartnereFullført
-
Washington University School of MedicineNational Institute on Minority Health and Health Disparities (NIMHD); National...FullførtHelsekunnskap | Helseforsikring | Tilgjengelighet for helsetjenester | Informert beslutningstakingForente stater
-
Icahn School of Medicine at Mount SinaiNational Heart, Lung, and Blood Institute (NHLBI)Fullført
-
Washington University School of MedicineRobert Wood Johnson FoundationFullført
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RekrutteringAnatomisk stadium I brystkreft AJCC v8 | Anatomisk stadium IA brystkreft AJCC v8 | Anatomisk stadium IB brystkreft AJCC v8 | Anatomisk stadium II brystkreft AJCC v8 | Anatomisk stadium IIA brystkreft AJCC v8 | Anatomisk stadium IIB brystkreft AJCC v8 | Anatomisk stadium III brystkreft AJCC v8 | Anatomisk... og andre forholdForente stater
-
NYU Langone HealthRekruttering
-
Icahn School of Medicine at Mount SinaiMayo ClinicFullført
-
Unity Health TorontoFullført
-
University of DelawareHarvard Medical School (HMS and HSDM); National Institute on Drug Abuse... og andre samarbeidspartnereFullførtOpioidbruksforstyrrelseForente stater